Arthritis and Rheumatology publishes positive Phase II data on anifrolumab in lupus

Gaithersburg, Md, 14 November 2016 - AstraZeneca and its global biologics research and development arm, MedImmune, today announced that Arthritis and Rheumatology has published positive results from the Phase II trial of anifrolumab, an investigational monoclonal antibody that blocks all type 1 interferons, for the treatment of moderate to severe systemic lupus erythematosus (SLE or lupus).

read more